Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes.

Yutaro Ogawa,Takashi Nakahara,Yuwa Ando,Kenji Yamaoka,Yasutoshi Fujii,Shinsuke Uchikawa,Hatsue Fujino,Atsushi Ono,Eisuke Murakami,Tomokazu Kawaoka,Daiki Miki,Masami Yamauchi,Masataka Tsuge,Michio Imamura,Shiro Oka

European journal of gastroenterology & hepatology（2023）

引用 1|浏览5

暂无评分

摘要

SGLT2i use not only improves weight loss and blood glucose levels but also improves hepatic fibrosis by ameliorating hepatic steatosis and inflammation.

查看译文

关键词

nonalcoholic fatty liver disease,diabetes,sodium-glucose,fibroscan-aspartate

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要